数据
资源
版本对比
免费注册
预约演示
免费注册
BioVaxys
Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE
2024-04-03
·
BioSpace
免疫疗法
临床1期
疫苗
临床2期
VANCOUVER, B.C., April 3, 2024 /PRNewswire/ --
BioVaxys Technology Corp.
(CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("
BioVaxys
" or "Company") announced that it has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a Patent ("Patent") for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with
DPX
™. Part of the extensive Intellectual Property portfolio acquired by
BioVaxys
from the former
IMV, Inc
, this Patent was recently allowed in Japan and is currently pending in the European Union.
DPX
™ is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules. Its unique "no release" mechanism of action allows antigen presenting cells (APCs) to be attracted to the injection site, facilitating a robust and sustained immune response. The smallest dose of a currently approved vaccine is 0.1ml for
Sanofi-Pasteur
's
Fluzone
™ Intradermal Quadrivalent vaccine. Low dose volume delivery of
DPX
™ formulated B-cell epitope is designed to be delivered in single dose as low as 50µL to 90 µL. An epitope is the part of an antigen that the host's immune system recognizes, eliciting the immune response to an invading pathogen. It specifically binds to the corresponding antigen receptor on the immune cell (such as a B-cell). Whereas T-cells protect people from getting infected by destroying cancerous and infected cells, B-cells produce antibodies to fight
infection
.
BioVaxys
President and Chief Operating Officer Kenneth Kovan stated "Allowance of this important patent in the United States greatly expands the value of our IP and antigen delivery platform with potential partners. Having the unique ability to deliver B cell epitopes using a low dose
DPX
™ formulation is an attractive approach for packaging antigens for a range of
cancer
immunotherapeutics and therapeutic vaccines."
BioVaxys
also is pleased to announce it has entered the national phase in the United States, Canada, European Union, Japan, and Australia with its patent application for DPX™-survivin/MAGE A9 ("DPX™ SurMAGE"), a DPX™ formulation of the
tumor
-associated antigens
survivin
and MAGE A9 as a dual targeted immunotherapy. The survivins and MAGE-A9 are frequently over-expressed in various human
cancers
including bladder, lung and kidney, and correlate with a resistance to chemotherapy and aggressiveness of
tumors
, and both are recognized as important targets for
cancer
vaccines and therapeutics.
DPX
™ SurMAGE" recently completed a successful Phase I clinical study in Canada with
bladder cancer
patients conducted at
CHU de
Québec-
Université Laval
, and induced a robust peptide-specific T cell response. Kovan further added that "
BioVaxys
and the Phase 1 clinical study investigators see the potential with further evaluation of
DPX
™ SurMAGE, and are particularly excited by the proven ability of
DPX
™ to package multiple different antigens. We will be reconvening with the study team at
CHU de
Québec-
Université Laval
to plan further development." About
BioVaxys Technology Corp.
BioVaxys Technology Corp.
( ), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and its HapTenix© 'neoantigen'
tumor
cell construct platform for treating
cancers
, infectious disease, antigen desensitization, and other immunological fields. The Company's clinical stage pipeline includes
maveropepimut-S
which is in Phase II clinical development for
advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL)
and
platinum resistant ovarian cancer
, and
BVX-0918
, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen'
tumor
cell construct platform which is soon to enter Phase I in Spain for treating
refractive late-stage ovarian cancer
. The Company is also capitalizing on its
tumor
immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable
tumor
antigens.
BioVaxys
common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed "James Passin" James Passin, CEO +1 646 452 7054 Company Codes: Copenhagen:BIOV, OTC-BB:BVAXF, OTC-PINK:BVAXF, OTCQB:BVAXF
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
BioVaxys LLC
IMV Inc.
Sanofi Pasteur
[+2]
适应症
感染
肿瘤
膀胱癌
[+3]
靶点
survivin
药物
DPX BRAF/CPA
四价流感病毒裂解疫苗(Sanofi)
EMD-640744
[+1]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
第一三共ADC药物DS-8201专利调研实务指南
智慧芽生物医药
2024年3月全球首批及特殊审评药物报告
智慧芽生物医药
THR-β 激动剂药物进展及专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务